Masimo Co. (NASDAQ:MASI) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. trimmed its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 33.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90,901 shares of the medical equipment provider's stock after selling 46,492 shares during the quarter. Rockefeller Capital Management L.P. owned 0.17% of Masimo worth $15,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Verition Fund Management LLC purchased a new stake in Masimo in the third quarter worth about $245,000. Stifel Financial Corp purchased a new position in Masimo during the third quarter valued at approximately $229,000. MML Investors Services LLC boosted its position in shares of Masimo by 4.9% in the third quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider's stock worth $274,000 after purchasing an additional 96 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Masimo during the 3rd quarter valued at $519,000. Finally, Barclays PLC lifted its stake in shares of Masimo by 152.6% during the 3rd quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock valued at $5,329,000 after buying an additional 24,137 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Wells Fargo & Company lifted their price target on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Finally, Piper Sandler boosted their target price on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $194.80.

Masimo Trading Up 0.3 %

Shares of MASI traded up $0.47 during midday trading on Friday, hitting $152.15. The stock had a trading volume of 457,368 shares, compared to its average volume of 659,539. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $194.88. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The stock's 50 day moving average is $168.04 and its 200 day moving average is $164.91. The firm has a market cap of $8.22 billion, a PE ratio of 104.93 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. As a group, analysts forecast that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Activity at Masimo

In other news, COO Bilal Muhsin sold 30,000 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the transaction, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 16.90% of the stock is owned by corporate insiders.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.